IP Library › Granted Patent US 10,982,007
Granted Patent B2
US 10,982,007 · App. 15/465,439 · Granted Apr 20, 2021

Detection of a posttranslationally modified polypeptide by a bivalent binding agent

Inventors: Michael Gerg (Munich, DE); Dieter Heindl (Paehl, DE); Christian Klein (Bonstetten, CH); Alfred Mertens (Schriesheim, DE); Volker Schmid (Penzberg, DE); Michael Schraeml (Penzberg, DE); Monika Soukupova (Wessobrunn, DE); Michael Tacke (Munich, DE)
Assignee: Roche Diagnostics Operations, Inc.
C07K16/468G01N33/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,982,007
App. No.
15/465,439
Granted
Apr 20, 2021
Kind
B2
Abstract

A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.

Claims (3)

1. A bivalent binding agent capable of binding at least a first epitope and a second epitope of phosphorylated insulin-like growth factor-1 receptor (pIGF-1R) wherein the bivalent binding agent consists of: a first monovalent binder that specifically binds to a polypeptide epitope of SEQ ID NO:11, wherein the first monovalent binder consists of: a Fab′-fragment of mAb 1.4.168 and a first ssDNA of SEQ ID NO:6, the first monovalent binder having a dissociation constant (Kdiss) ranging from 5×10 −3 /sec to 1×10 −4 /sec; a second monovalent binder that specifically binds to a posttranslational polypeptide modification of SEQ ID NO:11 corresponding to phosphorylation of tyrosine residue 1346, wherein the second monovalent binder consists of: a Fab′-fragment selected from the group consisting of mAb 8.1.2 and mAb 30.4.33 and a second ssDNA of SEQ ID NO:5, the second monovalent binder having a Kdiss ranging from 5×10 −3 /sec to 1×10 −4 /sec; and a linker selected from the group consisting of SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29, linking the first monovalent binder to the second monovalent binder, the bivalent binding agent having a Kdiss of 3×10 −5 /sec or less.

2. The bivalent binding agent of claim 1 , wherein the linker has a length of 6 to 100 nm.

3. The bivalent binding agent of claim 1 , wherein the linker is an L-DNA-linker.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2017
From: GERG, MICHAEL; HEINDL, DIETER; MERTENS, ALFRED; SCHMID, VOLKER; SCHRAEML, MICHAEL; SOUKUPOVA, MONKA; TACKE, MICHAEL; KLEIN, CHRISTIAN
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 042615/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2017
From: ROCHE DIAGNOSTICS GMBH
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 042615/0064 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2017
From: GERG, MICHAEL; HEINDL, DIETER; MERTENS, ALFRED; RUTZ, CHRISTOPH; SCHRAEML, MICHAEL; SOUKUPOVA, MONIKA; SUSTMANN, CLAUDIO; TACKE, MICHAEL; VAN DIECK, JAN
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 042615/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2017
From: ROCHE DIAGNOSTICS GMBH
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 042615/0526 →
Priority Claims (2)
EP 10196687 · Dec 23, 2010 · regional
EP 11173832 · Jul 13, 2011 · regional
Continuity (3)
Continuation 13923618 · Jun 21, 2013
Continuation PCTEP2011073560 · Dec 21, 2011
Related Publication 20170275381A1 · Sep 28, 2017